Clinicopathological and prognostic characteristics of CD33-positive multiple myeloma. - Wikidata - awgldk - TriplyDB

Clinicopathological and prognostic characteristics of CD33-positive multiple myeloma.

Clinicopathological and prognostic characteristics of CD33-positive multiple myeloma.

http://www.wikidata.org/entity/Q33371875

about

Expression of myeloid antigen in neoplastic plasma cells is related to adverse prognosis in patients with multiple myeloma.Small-lymphoid cells and myeloid antigen expression in a patient with IgG myeloma: A case report.Biclonal light chain gammopathy with aberrant CD33 expression in secondary plasma cell leukemia.Immunophenotyping in multiple myeloma and related plasma cell disorders.Association of CD117 and HLA-DR expression with shorter overall survival and/or progression-free survival in patients with multiple myeloma treated with bortezomib and thalidomide combination treatment without transplantation

P2860

Q33786986-2A895CCE-0C3B-4844-B075-0631BF433F3F Q36640775-14D69829-5A94-4391-94C2-C23E43C816A0 Q37228906-9E1A2E95-74A7-4ECF-8136-856ED40DB30C Q37812870-8A5182D6-880F-4D6B-BE96-599D851D1BEF Q57788806-B7D91FE1-63E3-4B2D-998C-F81362EF2CE6

P2860

Clinicopathological and prognostic characteristics of CD33-positive multiple myeloma.

http://www.wikidata.org/entity/Q33371875

description

2006 nî lūn-bûn

@nan

2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Clinicopathological and prognostic characteristics of CD33-positive multiple myeloma.

@ast

Clinicopathological and prognostic characteristics of CD33-positive multiple myeloma.

@en

type

label

Clinicopathological and prognostic characteristics of CD33-positive multiple myeloma.

@ast

Clinicopathological and prognostic characteristics of CD33-positive multiple myeloma.

@en

prefLabel

Clinicopathological and prognostic characteristics of CD33-positive multiple myeloma.

@ast

Clinicopathological and prognostic characteristics of CD33-positive multiple myeloma.

@en

P1433

Q33371875-13A50A88-9EA9-4808-B17F-50E5181D0C2C

P1476

Q33371875-D061C8A9-D153-458B-A5C3-9BCD1E08784D

P2093

Q33371875-21AE3CEB-A32F-4743-83DF-D08B801F0DAA

Q33371875-25F5D035-A03F-47D5-BBE8-3651779DDA7A

Q33371875-26ACFBAD-D1A7-4EE2-824E-3FC1E428B70F

Q33371875-3F47A8C6-2C0A-459D-88EE-76CEBEA7AA72

Q33371875-5692AA68-CC35-4AD0-819D-31E29FE84DED

Q33371875-5D68279E-42C4-4180-89D8-62BB041434C9

Q33371875-6898CBC6-0F08-49A9-A036-140F348F16C1

Q33371875-7D9C2F8D-0CBE-47ED-8C03-B249A8FC11F6

Q33371875-7FD946C3-EC10-4418-A7A5-38216B22E07F

Q33371875-A992AB77-B15C-4872-A370-D3182992C2C7

P2860

Q33371875-377E3309-0A81-4D32-99C8-6F9368CA8AB6

Q33371875-7CA1F3B1-8C89-4C18-90C9-DAB883C01463

Q33371875-E34E9D57-F92F-48DB-A51D-B820DE9C4D0D

Q33371875-F2ACB610-0042-43A0-BEC2-ED4E6B090660

P304

Q33371875-5ACE924F-3FB9-4286-AFF0-821BF85D8CFA

P31

Q33371875-55B7D654-C685-494A-AE29-F63DDB91A142

P356

Q33371875-F1383E96-EB1F-46FB-ACE1-913B6CE5F180

P433

Q33371875-D8FF66B1-D312-4AAF-BFC4-14703C7FF028

P478

Q33371875-892A1B19-E0F5-4352-9BC2-CB037282D702

P577

Q33371875-3529E336-87B0-49C0-961F-308C3ED9A4DF

P5875

Q33371875-41C593D6-FD08-419F-A99D-16D1DAEA40CA

P698

Q33371875-89B63E1B-D380-4D06-8164-A7CDA7406B4B

P356

J.1600-0609.2006.00661.X

P1433

European Journal of Haematology

P1476

Clinicopathological and prognostic characteristics of CD33-positive multiple myeloma.

@en

P2093

Akihiro Takeshita

http://www.w3.org/2001/XMLSchema#string

Kaori Takeshita

http://www.w3.org/2001/XMLSchema#string

Kazunori Ohnishi

http://www.w3.org/2001/XMLSchema#string

Kazuyuki Shigeno

http://www.w3.org/2001/XMLSchema#string

Kenji Nara

http://www.w3.org/2001/XMLSchema#string

Kensuke Naito

http://www.w3.org/2001/XMLSchema#string

Miki Kobayashi

http://www.w3.org/2001/XMLSchema#string

Naohi Sahara

http://www.w3.org/2001/XMLSchema#string

Ryuzo Ohno

http://www.w3.org/2001/XMLSchema#string

Sadahiro Tamashima

http://www.w3.org/2001/XMLSchema#string

P2860

Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).

Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo.

Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.

P304

14-18

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1600-0609.2006.00661.X

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

77

http://www.w3.org/2001/XMLSchema#string

P577

2006-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6957257

http://www.w3.org/2001/XMLSchema#string

P698

16827882

http://www.w3.org/2001/XMLSchema#string